Keytruda

Ivonescimab tops Keytruda in overall survival for first time in lung cancer trial

Akeso and Summit Therapeutics announced on September 2 that their bispecific antibody ivonescimab achieved a statistically significant overall survival improvement over Merck's blockbuster Keytruda in a Phase 3 trial treating PD-L1-positive non-small cell lung cancer, marking the first time a…